Sylvia Mcbrinn - Jun 15, 2021 Form 4/A - Amendment Insider Report for BioAtla, Inc. (BCAB)

Role: Director
Signature: /s/ Christian Vasquez, as Attorney-in-Fact for Sylvia McBrinn
Stock symbol: BCAB
Transactions as of: Jun 15, 2021
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 6/17/2022, 07:56 PM
Date Of Original Report: Jun 17, 2021
Next filing: Jun 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCAB	Stock Option (right to buy)	Award	$0	+18.9K		$0.00	18.9K	Jun 15, 2021	Common Stock	18.9K	$39.64	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 17, 2021, the reporting person filed a Form 4 in respect of an option covering 24,615 shares. Such option was granted on June 15, 2021 pursuant to the Company's non-employee director compensation policy. The Company subsequently determined that 5,695 of the shares comprising such award were null and void upon grant as a result of the $750,000 annual limit for non-employee director compensation under its 2020 Equity Incentive Plan.
F2	1/3 of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 15, 2022 or (b) the next annual meeting of stockholders, and 1/36th of the total number of shares shall vest monthly thereafter, subject to the reporting person continuing to provide services to the Company through the vesting date.

Content

On June 17, 2021, the reporting person filed a Form 4 in respect of an option covering 24,615 shares. Such option was granted on June 15, 2021 pursuant to the Company's non-employee director compensation policy. The Company subsequently determined that 5,695 of the shares comprising such award were null and void upon grant as a result of the $750,000 annual limit for non-employee director compensation under its 2020 Equity Incentive Plan.

1/3 of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 15, 2022 or (b) the next annual meeting of stockholders, and 1/36th of the total number of shares shall vest monthly thereafter, subject to the reporting person continuing to provide services to the Company through the vesting date.